Lung volume reduction surgery (LVRS) originally proposed by
Brantigan and colleagues1– and revived by Cooper and
colleagues,2– has become a new therapeutic option for
patients with end-stage emphysema, a disease that is frustratingly
difficult to treat. Although LVRS has been greeted with enthusiasm by
many physicians, skepticism on the safety and efficacy of this surgical
intervention in comparison to conventional medical therapy has
arisen.3,,4